High-glucose environment inhibits p38MAPK signaling and reduces human β-3 expression in keratinocytes

Molecular Medicine

Volumn 17, Issue 7-8, 2011, Pages 771-779

  Lan, Cheng Che E ^a,b   Wu, Ching Shuang ^c   Huang, Shu Mei ^a,d   Kuo, Hsuan Yu ^a   Wu, I Hui ^a   Wen, Chien Hui ^e   Chai, Chee Yin ^e   Fang, Ai Hui ^f   Chen, Gwo Shing ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^e Department of Pathology ^*  (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADVANCED GLYCATION END PRODUCT; BETA DEFENSIN 3; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INVOLUCRIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 1; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; KERATINOCYTE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; SKIN DEFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOZOCIN DIABETES; SUPERNATANT; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ANIMALS; BETA-DEFENSINS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; IMIDAZOLES; KERATINOCYTES; MALE; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SKIN; TOLL-LIKE RECEPTOR 2; WOUND HEALING;

EID: 79960733517     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2010.00091     Document Type: Article

References (41)

1. Abdulrazak A, Bitar ZI, Al-Shamali AA, Mobasher LA. (2005) Bacteriological study of diabetic foot infections. J. Diabetes Complications.19:138-41.
2. Calvet HM, Yoshikawa TT. (2001) Infections in diabetes. Infect. Dis. Clin. North. Am. 15:407-21.
3. Muller LM, et al. (2005) Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin. Infect. Dis. 41:281-8.
4. Shah BR, Hux JE. (2003) Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 26:510-3.
5. Delamaire M, et al. (1997) Impaired leucocyte functions in diabetic patients. Diabet. Med. 14:29-34.
6. Gallacher SJ, et al. (1995) Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet. Med.12:916-20.
7. Sheetz MJ, King GL. (2002) Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 288:2579-88.
8. Lan CC, Liu IH, Fang AH, Wen CH, Wu CS. (2008) Hyperglycaemic conditions decrease cultured keratinocyte mobility: implications for impaired wound healing in patients with diabetes. Br. J. Dermatol. 159:1103-15.
9. Lan CC, Wu CS, Kuo HY, Huang SM, Chen GS. (2009) Hyperglycaemic conditions hamper keratinocyte locomotion via sequential inhibition of distinct pathways: new insights on poor wound closure in patients with diabetes. Br. J. Dermatol.160:1206-14.
10. Lehrer RI, Ganz T. (2002) Defensins of vertebrate animals. Curr. Opin. Immunol. 14:96-102.
11. Froy O, Hananel A, Chapnik N, Madar Z. (2005) Differential expression of rat beta-defensins. IUBMB Life. 57:41-3.
12. Yang D, Biragyn A, Kwak LW, Oppenheim JJ. (2002) Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 23:291-6.
13. Ali RS, et al. (2001) Expression of the peptide antibiotics human beta defensin-1 and human beta defensin-2 in normal human skin. J. Invest. Dermatol.117:106-11.
14. Becker MN, Diamond G, Verghese MW, Randell SH. (2000) CD14-dependent lipopolysaccharideinduced beta-defensin-2 expression in human tracheobronchial epithelium. J. Biol. Chem.275:29731-6.
15. Fulton C, Anderson GM, Zasloff M, Bull R, Quinn AG. (1997) Expression of natural peptide antibiotics in human skin. Lancet. 350:1750-1.
16. Jang BC, et al. (2004) Up-regulation of human beta-defensin 2 by interleukin-1beta in A549 cells: involvement of PI3K, PKC, p38 MAPK, JNK, and NF-kappaB. Biochem. Biophys. Res. Commun.320:1026-33.
17. Jia HP, et al. (2001) Discovery of new human beta-defensins using a genomics-based approach. Gene. 263:211-8.
18. Singh PK, et al. (1998) Production of betadefensins by human airway epithelia. Proc. Natl. Acad. Sci. U. S. A. 95:14961-6.
19. Sorensen OE, et al. (2005) Differential regulation of beta-defensin expression in human skin by microbial stimuli. J. Immunol. 174:4870-9.
20. Goldstein EJ, Citron DM, Nesbit CA. (1996) Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases. Diabetes Care. 19:638-41.
21. Kisich KO, et al. (2007) The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J. Invest. Dermatol. 127:2368-80.
22. Lan CC, et al. (2005) FK506 promotes melanocyte and melanoblast growth and creates a favorable milieu for cell migration via keratinocytes: Possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br. J. Dermatol. 153:498-505.
23. Jarboe E, et al. (1998) Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. Diagn. Microbiol. Infect. Dis. 30:197-203.
24. Sorensen OE, et al. (2006) Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor. J. Clin. Invest. 116:1878-85.
25. Midorikawa K, et al. (2003) Infect. Immun. 71:3730-9.
26. Kawai K, Shimura H, Minagawa M, Ito A, Tomiyama K, Ito M. (2002) Expression of functional Toll-like receptor 2 on human epidermal keratinocytes. J. Dermatol. Sci. 30:185-94.
27. Schroder NW, et al. (2003) Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278:15587-94.
28. McDermott AM, et al. (2003) Defensin expression by the cornea: multiple signalling pathways mediate IL-1beta stimulation of hBD-2 expression by human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 44:1859-65.
29. Ogushi K, et al. (2001) Salmonella enteritidis FliC (flagella filament protein) induces human beta-defensin-2 mRNA production by Caco-2 cells. J. Biol. Chem. 276:30521-6.
30. Wada A, et al. (2001) Helicobacter pylori-mediated transcriptional regulation of the human betadefensin 2 gene requires NF-kappaB. Cell. Microbiol.3:115-23.
31. Whitmarsh AJ, Davis RJ. (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J. Mol. Med.74:589-607.
32. Brownlee M. (1994) Lilly Lecture 1993. Glycation and diabetic complications. Diabetes. 43:836-41.
33. Alikhani M, et al. (2007) Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am. J. Physiol. Cell. Physiol.292:C850-6.
34. Duraisamy Y, et al. (2003) Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine. Mol. Cell. Biochem. 246:143-53.
35. Giardino I, Fard AK, Hatchell DL, Brownlee M. (1998) Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant- induced apoptosis. Diabetes. 47:1114-20.
36. Teixeira AS, Caliari MV, Rocha OA, Machado RD, Andrade SP. (1999) Aminoguanidine prevents impaired healing and deficient angiogenesis in diabetic rats. Inflammation. 23:569-581
37. Yavuz D, et al. (2005) Collagen ultrastructure and TGF-beta1 expression preserved with aminoguanidine during wound healing in diabetic rats. Endocr. Res. 31:229-43.
38. Lambert S, Frankart A, Poumay Y. (2010) p38 MAPK-regulated EGFR internalization takes place in keratinocyte monolayer during stress conditions. Arch. Dermatol. Res. 302:229-33.
39. Lander HM, et al. (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272:17810-4.
40. Yeh CH, et al. (2001) Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes.50:1495-504.
41. Hirsch T, et al. (2009) Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J. Gene. Med. 11:220-8.